GB2587222A - Device for destroying extended beta-amyloid - Google Patents

Device for destroying extended beta-amyloid Download PDF

Info

Publication number
GB2587222A
GB2587222A GB1913523.5A GB201913523A GB2587222A GB 2587222 A GB2587222 A GB 2587222A GB 201913523 A GB201913523 A GB 201913523A GB 2587222 A GB2587222 A GB 2587222A
Authority
GB
United Kingdom
Prior art keywords
patient
pulse
transducer
electromagnetic
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB1913523.5A
Other versions
GB201913523D0 (en
Inventor
Andrew Walker David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dglp Ltd
Original Assignee
Dglp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dglp Ltd filed Critical Dglp Ltd
Priority to GB1913523.5A priority Critical patent/GB2587222A/en
Publication of GB201913523D0 publication Critical patent/GB201913523D0/en
Priority to PCT/GB2020/052256 priority patent/WO2021053339A1/en
Publication of GB2587222A publication Critical patent/GB2587222A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/02Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/40Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/3603Control systems
    • A61N1/36031Control systems using physiological parameters for adjustment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0537Measuring body composition by impedance, e.g. tissue hydration or fat content
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/004Magnetotherapy specially adapted for a specific therapy

Abstract

A device for the destruction of extended beta-amyloid proteins (those which have been appended with tau proteins and peptide fragments) in the blood of a patient. The device comprises a strap for attaching the device to a patient’s forearm, a housing, a transducer configured to emit an electromagnetic pulse into the patient, a power supply, and a control unit configured to operate the transducer to emit a pulse, receive the reflection of that pulse from extended beta-amyloid proteins within the blood of the patient, and then operate the transducer to emit electromagnetic radiation (pulsed electromagnetic field therapy, PEMFT) which triggers the white blood cells to destroy the extended beta-amyloids within the blood of the patient. The device may be of use in the treatment of Alzheimer’s disease.

Description

DEVICE FOR DESTROYING EXTENDED BETA MYLOTD
The present invention relates generally to a device for destroying extended BetaAmyloid protein within the blood of a patient and finds particular, although not exclusive, utility in the treatment of Alzheimer's disease (AD).
Pulsed electromagnetic field therapy (PELMET) has been used successfully in the management of postsurgical pain and edema, the treatment of chronic wounds, and in facilitating vasodilatation and angiogenesis. Conventional PELMET enables modulation of Calcium (Can binding to Calmodulin (CaM), upon a transient increase in intracellular Calcium when homeostasis is interrupted. Disruption of the tightly regulated Ca' balance in cells is the natural signal to provoke the endogenous tissue repair and regeneration mechanism, hence the apparent simple acceleration of normal healing activity by targeted PEW signals. Ca/CaM catalyzes Endothelial Nitric Oxide Synthase (eNOS), which allows the PEMF signal to modulate the release of Nitric Oxide (NO) from eNOS and potentially affect the entire tissue repair pathway, from pain and edema to angiogenesis, bone and tissue regeneration, and other regenerative actions. Because of the unique biologic mechanism of the PEMF effect, this modality can be combined quite effectively with other therapies for additive or supra-additive effects to promote pain relief, healing, and recovery.
The present application identifies an entirely new application of PEMFT, and a new apparatus permitting fine control of the pulsed electromagnetic field.
Alzheimer's disease is characterized microscopically by the combined presence of 2 classes of abnormal structures: extracellular amyloid plaques and intraneuronal neurofibfillary tangles, both of which comprise highly insoluble, densely packed filaments.
The soluble building blocks of these structures are Beta-Amyloid peptides for plaques and Tau for tangles. Beta-Amyloid peptides are proteolytic fragments of the transmembrane amyloid precursor protein, whereas Tau is a brain-specific, iixon-enriched microtubuleassociated protein. When such deposits form in the brain, neurodegenerative processes are triggered that lead to loss of memory and cognitive ability.
There are five types of leukocyte or white blood cell, each of which reacts to a specific chemical stimulus. The present invention seeks to mimic that stimulus, triggering the white blood cells to destroy the extended Beta-Amyloid protein.
According to a first aspect of the present invention, there is provided a device for destroying extended Beta-Amyloid protein within the blood of a patient, the device comprising: a strap for attachment to a forearm of the patient; a housing attached to the strap; at least one transducer configured to transmit a pulse into the forearm of the patient; a control unit configured to: operate the at least one transducer to emit a pulse; receive a signal from the at least one transducer indicative of a reflection of the pulse from extended Beta-Amyloid protein within the blood of the patient; and in response to receiving the signal, operate the at least one transducer to emit electromagnetic modulations that trigger white blood cells to destroy the extended Beta-Amyloid protein within the blood of the patient; and a power supply for supplying electrical energy to the control unit.
The foreman may comprise an inner foreman, and or a location approximately three finger-widths from the wrist of the patient, for example the location for determining the radial pulse of the patient and/or called Pericardiam6" Nei Guan (P6 or PC6) in the field of acupuncture.
Beta-Airirloid is best known as the mistiaided Peptide that is in solved in the pathogenesis of Alidieimer's disease, and it is currently the primary thcraneritic target in attempts to arrest the course of this disease. *this notoriety' has overshadowed eaddenct that Beta-Anislirid serves scver it can physiological illunyiroirj. beta-A17:VIOid present throughout the lr[CST:an, it hds fOUTid in all venebrates cx;in-tincd thus fur, and its molecular seQuence shows a high degree of conservation. these features are typical of a factor that contributes significantly to biological fitness, and this suggestion has been supported by e, device of functions that are beneficial for the brain. The putative roles r f7 include protecting the body from infections, repairing leaks in the blood-brain barrier, promoting recovery from injury, and regulatii z -.ynaptic function. Evidence for tbesys beneficial roles comes front rifts; arid /7/ite tudics, which haye shown that the cellular production of Beta-Arm:aid rapidly increases it: response to a physiological challenge and often tlimiitishes upon recovery, The Tnv cntor has proven that in an Alzheimer's sufferer a chemical attraction occurs in the viscous flow whereby tissue that has broken off the arterial wall, attaches to a normal Beta-Amyloid protein. This combination attracts a Tau attachment and peptide fragments to the original Beta-Amyloid protein; referred to in this document as extended Beta-Amaloid protein' or 'extended protein'.
This extended protein has a number of characteristics that both contribute to Alzheimer's disease, and make it readily identifiable. The extended protein now differs from the normal Beta-Amyloid protein in that, it has increased in size and formation (as a result of the attached items) and is also 'sticky' due to the Peptide fragments.
In an Alzheimer's patient, the extended proteins accumulate to form plaques that block the synapses, the space between two nerve cells which transmit information, in the brain. This has the result of impairing memory and cognitive functions in the sufferer and ultimately causing death.
The invention uses calculated electromagnetic pulses, to identify a specific entity of known makeup and characteristics (i.e. the extended protein). The signature of the extended protein now differs from the original Beta-Amyloid protein, in that it has greater mass and a different formation, due to the addition of the Tau attachment and peptide fragments. It will therefore respond differently in the Hood stream (viscous flow) making it easy to identify by reflected velocity and delivery time.
The device emits individual PEW low-energy, time-accurate magnetic pulse frequencies which are used to identify the extended protein by its structural surface modification, density and displacement within the viscous flow.
Once the extended protein has been identified it is subjected to a modulation which mimics the mathematical signature of an antibody when marking a pathogen for destruction by neutrophils (White Blood Cells /leucocytes). Using the natural process of the immune system, Neutrophils now destroy the extended protein disguised as a pathogen using a process called Phagocytosis.
So, simply put, our invention is able to identify the extended protein then agitate it such that the body's own immune system identifies it as an alien form in the blood stream and deals with it as it would any other foreign or invading body.
The housing and/or strap may comprise a shell and/or may be contoured. The housing and/or strap may be semi-rigid; that is, the housing and/or strap may mould to the contour of the patient's forearm. The housing and/or strap may comprise a cold-moulded polyurethane. The housing and/or strap may be configured such that body temperature (for example a temperature of the forearm of the patient) may be sufficient to mould the strap exactly to a contour of the patient's forearm. The housing may be sealed, for example to prevent ingress of moisture and/or dirt.
The transducer may be coupled to a patient's skin via electrodes. The electrodes may comprise pads, and may be locatable on the surface of the skin of the patient (i.e. not to penetrate and/or pierce the skin).
Alternatively or additionally, the device may further comprise a Nano-patch. The Nano-patch may comprise a plurality of Nano-wires. The Nano-wires may be bonded together to form an array of parallel wires. Bonding may be via adhesive. The Nano-patch may be flexible. The Nano-patch may have a thickness of between 2 and 20 microns, in particular between 4 and 10 microns, more particularly approximately 6 microns. Each Nano wiremay have a length approximately equal to a thickness of the Nano-patch. Each Nano-wire may he orientated across the thickness of the Nano-patch.
The Nano-wires may comprise magnetic Nano-wires. The Nano-wires may he grown. The Nano-patch may he placed in a cold moulded configuration in the housing.
The device may be configured to transmit an electromagnetic pulse into the forearm of the patient.
The at least one transducer may comprise only one transducer or two, three, four or more transducers. The or each transducer may comprise a magnetic flux transducer. The or each transducer may be driven by a respective chipset comprising multiple layers (e.g. two or three layers).
The control unit may comprise a magnetic flux control unit. The control unit may comprise one or more chip sets, e.g. off-the shelf and/or programmable chipset(s).
The power supply may comprise a battery and/or kinetic energy recovery unit, for generating electrical power from kinetic movement of the patient, and in particular the foreatni. The kinetic energy recovery unit may comprise a Nano-frequency kinetic generator.
One or more of the at least one transducer, control unit, and power supply may also be arranged within the housing. However, other arrangements are also possible.
The electromagnetic pulse may comprise at least one electromagnetic pulse, for example only one electromagnetic pulse, or two electromagnetic pulses or more.
The device may be configured to continually transmit an electromagnetic pulse, or a sequence of electromagnetic pulses, at predefined intervals. The intervals may be fixed, variable, or vary in length based on sense signals (e.g. from sensors).
For example, sense signals may be derived from Impedance Spectroscopy, which measures electrical properties of materials, e.g. the conductance (or resistance) and the reactance as a Function of applied alternative current frequency, therefore providing a quantitative analysis of the effect of the device on the patient. Alternatively or additionally, four rogue cells that have been extended by a Tau attachment and a peptide inducement which alters the density making them easy to identify by reflected velocity and delivery time.
The electromagnetic modulation may comprise a broad-spectrum frequency set, in particular between 4 and 15 MHz, more particularly between 5 and 12 MHz, more particularly between 6 and 10 MHz. For example, the electromagnetic modulation may span an entire frequency range between 6 and 10 MHz, may include sub frequency ranges spaced between 6 and 10 MHz, and/or may span a frequency range of between 6 and 10 MHz in width.
The electromagnetic modulation (for instance of a single pulse, or within a sequence of pulses) may be emitted over a period of up to 100 microseconds.
Tn the case of more than one electromagnetic pulse within a sequence of pulses, each electromagnetic pulse may be spaced from another by approximately 100 nanoseconds. This may comprise a spacing of respective peaks of each burst.
The or each electromagnetic pulse may be directed into the patient's viscous/blood flow, for instance within the radial artery.
Components within the housing may be coated with hard dielectric coatings that 20 may have extremely high damage thresholds.
The device may further comprise diffuse cavity reflectors, which may be arranged to give a high degree of modulations and uniformly, and therefore an optimum burst quality.
In some arrangements, there may he a single Nano-patch for all transducers and/or sensors. Tn alternative arrangements, there may be separate Nano-patches and/or Nano-wires for some or each of the transducers, transducer layers and/or sensors. Net vertical electron may be generated in the charged deposition and/or surrounding atoms. The charged particles may result in the creation of electromagnetic modulations. A negative pulse current to the electromagnetic pulse charged electrons may move outward faster in the Nano scale and, the electromagnetic pulse being much heavier, may provide charged ions which may automatically separate the charged bursts. The region closest to the burst point may have a positive charge and, as the burst diminishes, net negative charges may occur, which may cause a swirl in the viscous material (e.g. blood). Separation may occur in the combined charges within the target environment. At one tenth of a microsecond a second burst may attain its maximum strength, which then may fall off and may create movement in the blood flow. Repeated controlled disturbances may result in a net micro electron current.
The above and other characteristics, features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawing(s), which illustrate, by way of example, the principles of the invention. This description is given for the sake of example only, without limiting the scope of the invention. the reference figure(s) quoted below refer to the attached drawing(s).
Figure 1 shows circuit diagram of a dev ce for destroying extended Beta-Amyloid.
The present invention will be described with respect to certain drawings but the invention is not limited thereto but only by the claims. The drawings described are only schematic and are non-limiting. Each drawing may not include all of the features of the invention and therefore should not necessarily be considered to be bean embodiment of the invention. In the drawings, the size of some of the elements may be exaggerated and not drawn to scale for illustrative purposes. 'the dimensions and the relative dimensions do not correspond to actual reductions to practice of the invention.
Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar element and not necessarily for describing a sequence, either temporally, spatially, in ranking or in any other manner. It is to he understood that the tams so used are interchangeable under appropriate circumstances and that operation is capable in other sequences than described or illustrated herein. Likewise, method steps described or claimed in a particular sequence may be understood to operate in a different sequence.
Moreover, the terms top, bottom, over, under and the like in the description and the claims are used for descriptive purposes and not necessarily for describing relative positions. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that operation is capable in other orientations than described or illustrated herein.
It is to be noticed that the term "comprising", used in the claims, should not be interpreted as being restricted to the means listed thereafter; it does not exclude other elements or steps. Tt is thus to he interpreted as specifying the presence of the stated features, integers, steps or components as referred to, but does not preclude the presence or addition of one or more other features, integers, steps or components, or groups thereof. Thus, the scope of the expression "a device comprising means A and B" should not be limited to devices consisting only of components A and B. It means that with respect to the present invention, the only relevant components of the device are A and B. Similarly, it is to be noticed that the term "connected", used in the description, should not be interpreted as being restricted to direct connections only. 'thus, the scope of the expression "a device A connected to a device B" should not be limited to devices or systems wherein an output of device A is directly connected to an input of device B. It means that there exists a path between an output of A and an input of B which may he a path including other devices or means. "Connected" may mean that two or more elements are either in direct physical or electrical contact, or that two or more elements are not in direct contact with each other but yet still co-operate or interact with each other.
For instance, wireless connectivity is contemplated.
Reference throughout this specification to "an embodiment" or "an aspect" means that a particular feature, structure or characteristic described in connection with the elf Ibodinlent or aspect is irldUded in at least one embodiment or aspect of the present invention. Thus, appearances of the phrases "in one embodiment", "in an embodiment", or "in an aspect" in various places throughout this specification are not necessarily all referring to the same embodiment or aspect, but may refer to different embodiments or aspects. Furthermore, the particular features, structures or characteristics of any one embodiment or aspect of the invention may he combined in any suitable manner with any other particular feature, structure or characteristic of another embodiment or aspect of the invention, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments or aspects.
Similarly, it should be appreciated that in the description various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. This method of disclosure, however, is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Moreover, the description of any individual drawing or aspect should not necessarily be considered to be an embodiment of the invention. Rather, as the following claims reflect, inventive aspects lie in fewer than all features of a single foregoing disclosed embodiment. Thus, the claims following the detailed description are hereby expressly incorporated into this detailed description, with each claim standing on its own as a separate embodiment of this invention.
Furthermore, while some embodiments described herein include some features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form yet further embodiments, as will be understood by those skilled in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.
In the description provided herein, numerous specific details are set forth.
However, it is understood that embodiments of the invention may he practised without these specific details. In other instances, well-known methods, structures and techniques have not been shown in detail in order not to obscure an understanding of this description.
Tn the discussion of the invention, unless stated to the contrary, the disclosure of alternative values for the upper or lower limit of the permitted range of a parameter, coupled with an indication that one of said values is more highly preferred than the other, is to be construed as an implied statement that each intermediate value of said parameter, lying between the more preferred and the less preferred of said alternatives, is itself preferred to said less preferred value and also to each value lying between said less preferred value and said intermediate value.
The use of the term "at least one" may mean only one in certain circumstances.
The use of the term "any" may mean "all" and/or "each" in certain circumstances.
The principles of the invention will now he described by a detailed description of at least one drawing relating to exemplary features. It is clear that other arrangements can be configured according to the knowledge of persons skilled in the art without departing from the underlying concept or technical teaching, the invention being limited only by the terms of the appended claims.
Figure 1 shows a circuit diagram of a device for targeting and destroying the extended Beta-Anayloid protein, comprising two chipsets DGLP1 and DGLP2, each with eight respective pins (indicated as 1 to 8 on each chipset), of which only seven are used (pin 5 is not used in each case). DGLP1 and DGLP2 may comprise respective 555 timer ICs. The circuit is powered by a 3V DC power source B1, the power being controlled by Switch 2. Resistors Ri to R11, variable resistors P1 to P3, capacitors Cl to C5, diodes D1 to D3, transistors TR1 to Ilt3 and Switch 1 mediate control signals from the two chipsets DGI,P1 and DGI,P2 to the electrodes (e.g. conducting pads) El and E2 via a transformer Tl.
Under typical operation, Ri is 201 kF2, R3 is 5.01 A14, R9 is 167 lit?, R10 is 6.8 kF2 and C2 is 47 nF. However, in order to tailor the device to a particular user, various different values may be chosen, for instance to suit the user's 1)1 1 _ viscosity. For example, to shift the device to a higher frequency, the following alternative values may be chosen: Ri is 6.8 lscl, R3 is 167 k52, R9 is 236 k4, R10 is 9.6 kc2 and C2 is 100 p1± In alternative arrangements, autocalibration may he achieved by the device detecting a patient's blood viscosity and effectively setting the above-mentioned components to suitable values.
DGT,P1 controls emission of electromagnetic impulses (trans-cutaneous pulses) to be delivered to the viscous flow at a pulse rate of between 2-5 Hz.
Reflections of the impulses are interpreted by DGLP2 to determine the relative density of content within the viscous flow and specifically the presence of extended BetaAmyloid protein in the patient's viscous flow.
DG 22 mimics the electrical signals of a pathogen within the immune system, triggering white blood cells to attack and destroy the extended Beta-Amyloid protein.
Switch 1 and Switch 2 are controlled by the algorithms embedded in the device.
Switch 1 delivers power from the battery to the circuitry and Switch 2 (when Switch 1 is closed) controls the delivery of pulses into the viscous flow.
Switch 1 and Switch 2 may comprise respective 555 timer ICs, each of which include respective built-in electromagnetic reed switches. It is made from two ferrous reeds encased within a small glass tube-like envelope, which becomes magnetised and moves together when a magnetic field is moved towards the switch. The switch effectively works like a gate, or a bridge, in an electric circuit so when the two reeds are in contact, electricity can flow around the circuit operating the device. Unlike mechanical switches they do not require something or someone to physically flick them on or off, they are controlled completely by being in the close proximity to an invisible magnetic field.
Rhodium is used as the contact material in the reed switches due to its low contact resistance and resistance to corrosion.
As the current accesses the reed switch, it becomes a part of an clectro 'magnetic circuit' that includes the magnetic pulse. The two contacts become 'opposite magnetic poles', being attracted and snapping together. Tt doesn't matter which end of the electromagnetic pulse arrives first as the process is completely controlled by embedded code within DGLP1 and DGLP2: the contacts always polarize in opposite directions to attract and close. As in the drawing the switch is normally open or off, unless the switch is influenced by an electromagnetic pulse, which then switches it on and allows the pulse to flow through it.
In an alternative arrangement not shown in the figures, one or both chipset(s) may comprise a Linux digital embedded Integrated Circuit (IC). One of the ICs is re-triggerable and a monostable multi-vibrator or gated latch; the other is a D flip-flop. The difference between a flip-flop and a gated latch is that in a flip-flop, the inputs are not enabled merely by the presence of a HIGH signal on the CLOCK input.
The re-triggerable monostable multi-vibrator produces pulses depending upon the value of an external capacitor and resistor.
Since the multi-vibrator is a dual TC, it is possible to generate two pulses with ease and exact calibration. These pulses are then separated from each other by increasing the external resistance of one multi-vibrator.
A potentiometer is added in series with the external resistor allowing for the calibration and finite adjustment of the pulse duration times.
These pulses are then used to clock and deliver the D flip-flop sequence, by setting the pulses apart by 20 nanoseconds, which allows the D to he clocked high then re-calibrated much lower to around 20 nanoseconds later than the original burst.
The re-triggerable monostable multi-vibrator needs a clock signal to repeat the pulses. A simple embedded timer is used to create a Linux clock tick of 1.3 kTTz. The timer is also built with micro potentiometers to allow adjustment of the frequency and duty cycle. All three ICs are powered using a simple kinetic regulator.
Fast rising signals may arrive at the specific components, for instance delivered in nanoseconds.
The PCB layout contains the majority of the components and trace routes required in the invention. Most of the nanosecond switching and pulse generation blocks are laid in further layers.
The first important trace is the dock signal coming from the embedded timer. This trace is routed as directly as possible to allow a good signal path to the re-triggerable monostable multi-vibrator embedded micro-chip.
The remaining traces that require calibration arc the pulses from the re-triggerable monostable multi-vibrator which clock and pre-set the D flip-flop in sequence. The length and width of these traces are closely monitored to prevent signal loss or degradation. The external resistor and capacitor are positioned close to the re-triggerable monostable multi-vibrator to create accurate calculated pulses.
These traces were designed to be wide to accelerate the signal quality. Around 100 mils of clearance are needed to prevent arcing between the traces and ground signals.
Ground signals are also designed wider than usual to help reduce ground paths interference.
The 20 nanosecond pulse from the pulse generation block is routed directly to the Tanux embedded driver with short wide traces, and the input power from the kinetic burst.
One switch is used for on/off power and the other turns the pulse generation block on/off. The board is also cut out near the jacks to allow them to sit level with the embedded chip.
Several components are added to the ground traces of the circuit. These allow free paths to the ground plane on the bottom layer.
Signals are generated through two 30 f.-2 matched transmission lines connected with a switch.
At t<0, a transmission line is kinetically powered to a pre-defined voltage VO.
At t=0, the switch is put to closed state, which results in the propagation of and (reflection) in opposite directions at the switch.
Eventually, both the waves superimpose to give a rectangular pulse, where the amplitude and pulse width can be calculated in a conventional manner.
There may be 4 Nano-wire tubes in an array. The Nano-tubes are also more powerful at the output port running at 1 5pF average power and peaking at 30pF.
The operation of a further transducer may bring the blood flow back to the optimum temperature, the flow of which may then pass through the brain and stimulate the synapses to dry the previously formed tangles and clumps. 1l

Claims (8)

  1. CLAIMS1. A device for destroying extended Beta-Amyloid protein thin the blood of a patient, the device comprising: a strap for attachment to a forearm of the patient; a housing attached to the strap; at least one transducer configured to transmit a pulse into the forearm of the patient; a control unit configured to: operate the at least one transducer to emit a pulse; receive a signal from the at least one transducer indicative of a reflection of the pulse from extended Beta-Amyloid protein within the blood of the patient; and in response to receiving the signal, operate the at least one transducer to emit electromagnetic modulation that triggers white blood cells to destroy the extended Beta-Amyloid protein within the blood of the patient; and a power supply for supplying electrical energy to the control unit.
  2. 2. The device of claim 1, wherein the housing is configured such that body temperature is sufficient to mould the strap exactly to a contour of the patient's forearm.
  3. 3. The device of claim 1 or claim 2, wherein the device further comprises a Nano-patch comprising a plurality of Nano wiresbonded together to form an array of parallel wires.
  4. 4. The device of any preceding claitn, wherein the at least one transducer comprises four transducers.
  5. 5. The device of any preceding claim, wherein the power supply comprises a kinetic energy recovery unit, for generating electrical power from kinetic movement of the patient.
  6. 6. The device of any preceding claim, wherein the electromagnetic pulse comprises a sequence of electromagnetic pulses, and the device is configured to continually transmit multiple sequences of electromagnetic pulses.
  7. 7. The device of any preceding claim, wherein the electromagnetic modulation may comprise a broad-spectrum frequency set.
  8. 8. The device of claim 6, wherein the sequence of electromagnetic pulses is emitted over a period of up to 100 microseconds.
GB1913523.5A 2019-09-19 2019-09-19 Device for destroying extended beta-amyloid Pending GB2587222A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1913523.5A GB2587222A (en) 2019-09-19 2019-09-19 Device for destroying extended beta-amyloid
PCT/GB2020/052256 WO2021053339A1 (en) 2019-09-19 2020-09-17 Device for destroying extended beta-amyloid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1913523.5A GB2587222A (en) 2019-09-19 2019-09-19 Device for destroying extended beta-amyloid

Publications (2)

Publication Number Publication Date
GB201913523D0 GB201913523D0 (en) 2019-11-06
GB2587222A true GB2587222A (en) 2021-03-24

Family

ID=68425546

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1913523.5A Pending GB2587222A (en) 2019-09-19 2019-09-19 Device for destroying extended beta-amyloid

Country Status (2)

Country Link
GB (1) GB2587222A (en)
WO (1) WO2021053339A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5743844A (en) * 1996-11-01 1998-04-28 Amei Technologies, Inc. High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system
JP2004321249A (en) * 2003-04-21 2004-11-18 Matsushita Electric Works Ltd Brain function activation apparatus and method
WO2013067512A1 (en) * 2011-11-04 2013-05-10 Ivivi Health Sciences, Llc Method and apparatus for electromagnetic treatment of cognition and neurological injury
US20140155733A1 (en) * 2002-02-14 2014-06-05 Gholam A. Peyman Method and composition for hyperthermally treating cells
WO2015157712A2 (en) * 2014-04-11 2015-10-15 Wristspace, Llc Wrist worn sensor
US20160106997A1 (en) * 2009-03-11 2016-04-21 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
US20190054308A1 (en) * 2017-08-18 2019-02-21 Sandhya Verma Pulsed Electromagnetic Field (PEMF) Therapy Whole Body Wellness Device to increase cells energy, strengthen immune system and promote cell regeneration
US20190217111A1 (en) * 2013-03-11 2019-07-18 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518959A (en) * 1999-06-08 2003-06-17 メディカル ブレイシング システムズ リミテッド PEMF biophysical stimulus field generator apparatus and method
US9014801B2 (en) * 2008-03-19 2015-04-21 The Board Of Trustees Of The University Of Illinois Electromagnetic field therapy delays cellular senescence and death by enhancement of the heat shock response
JP2018097874A (en) * 2013-05-07 2018-06-21 安東 秀夫 User interface device and service provision method
WO2018189393A1 (en) * 2017-04-14 2018-10-18 Regenlife Transcutaneous irradiation device and application to the treatment of neurodegenerative diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5743844A (en) * 1996-11-01 1998-04-28 Amei Technologies, Inc. High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system
US20140155733A1 (en) * 2002-02-14 2014-06-05 Gholam A. Peyman Method and composition for hyperthermally treating cells
JP2004321249A (en) * 2003-04-21 2004-11-18 Matsushita Electric Works Ltd Brain function activation apparatus and method
US20160106997A1 (en) * 2009-03-11 2016-04-21 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
WO2013067512A1 (en) * 2011-11-04 2013-05-10 Ivivi Health Sciences, Llc Method and apparatus for electromagnetic treatment of cognition and neurological injury
US20190217111A1 (en) * 2013-03-11 2019-07-18 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
WO2015157712A2 (en) * 2014-04-11 2015-10-15 Wristspace, Llc Wrist worn sensor
US20190054308A1 (en) * 2017-08-18 2019-02-21 Sandhya Verma Pulsed Electromagnetic Field (PEMF) Therapy Whole Body Wellness Device to increase cells energy, strengthen immune system and promote cell regeneration

Also Published As

Publication number Publication date
WO2021053339A1 (en) 2021-03-25
GB201913523D0 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
US3426748A (en) Stimulator analyzer and locater
Rinzel Excitation dynamics: insights from simplified membrane models
EP1482882B1 (en) Implantable device for preventing thrombus formation
BR112019000288A2 (en) implants that use ultrasonic waves to stimulate tissue
CA2892996C (en) Extracorporeal unit for inspecting the insulation of an electrical wire of an implanted medical device
SE9700396D0 (en) Heart stimulating device
JP2008544813A5 (en)
JP2010505550A5 (en)
US9955882B2 (en) System to monitor neural integrity
US10335594B2 (en) Desensitizing device
Hagiwara et al. Physiological properties of electroreceptors in the electric eel, Electrophorus electricus
KR20150064014A (en) Apparatus for use for providing information on at least one muscle in a patient
Hopkins Convergent designs for electrogenesis and electroreception
WO2021053339A1 (en) Device for destroying extended beta-amyloid
SE0104337D0 (en) An implantable heart stimulating device, a system including such a device and a lesser use of the system
CN203734651U (en) Three-key distributed safety sensing touch switch device
JP3204183U (en) Low frequency treatment device
CN106267591B (en) A kind of ultrasound electric needle therapeutic instrument
Combes et al. Conditional dendritic oscillators in a lobster mechanoreceptor neurone.
Kouzani et al. A head mountable deep brain stimulation device for laboratory animals
CN101432041B (en) Electromagnetic treatment apparatus for augmenting wound repair and method for using same
RU68316U1 (en) ELECTRODE DEVICE
Terasawa et al. A visual prosthesis with 100 electrodes featuring wireless signals and wireless power transmission
WO2005039694A1 (en) Improved cerebral electrostimulation device
JP2021512702A (en) Tissue stimulation method using spatial scanning of electric and magnetic fields